Understand the source comparison
KPV Help Rheumatoid Arthritis: Comparison of Approaches
DMARDs (methotrexate) Inhibits dihydrofolate reductase, suppresses T cell activation Phase 3 RCTs, decades of clinical use Moderate. Increased infection risk, hepatotoxicity monitoring required 6–12 weeks Gold standard first-line therapy with extensive safety
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DMARDs (methotrexate)
- Inhibits dihydrofolate reductase, suppresses T cell activation
- Phase 3 RCTs, decades of clinical use
- Moderate. Increased infection risk, hepatotoxicity monitoring required
- 6–12 weeks
- Gold standard first-line therapy with extensive safety data and proven disease modification
- Biologics (TNF-α inhibitors)
- Neutralizes circulating TNF-α via monoclonal antibodies
- Multiple Phase 3 RCTs, FDA-approved for RA
- High. Risk of tuberculosis reactivation, opportunistic infections
- 2–4 weeks
- Highly effective but expensive; requires screening for latent infections before initiation
- JAK inhibitors (tofacitinib)
- Blocks Janus kinase signaling, reducing cytokine receptor activity
- Phase 3 RCTs, FDA-approved 2012
- Moderate to high. Increased herpes zoster risk, lipid abnormalities
- Oral administration advantage; cardiovascular and thrombotic event concerns in certain populations
- KPV peptide
- Inhibits NF-κB nuclear translocation, reduces pro-inflammatory gene transcription
- In vitro and animal studies only; no Phase 2 human RA trials
- Unknown. No long-term human safety data
- Unknown. No clinical dosing studies
- Mechanistically interesting but unproven; requires rigorous Phase 2 trials before clinical consideration